US companies overusing Medicare outpatient PPS (prospective payment system), say hospitals
This article was originally published in Clinica
Executive Summary
Major US hospital groups have begun complaining about the device industry's aggressive use of the special new technology pass-through payment available under Medicare's outpatient prospective payment system (PPS). In a July 10 letter to Thomas Scully, the new administrator of the Centers for Medicare & Medicaid Services (CMS), the groups expressed concern that payments for new technologies might reduce the amount of money going for other care areas.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.